ANL Adlai Nortye Group Ltd.
$10.71▲ +1.23%
Healthcare
Other
After hours
$10.71▲ +0.00%
Oct 27, 4:00 PM ET
Volume 71.2K
Avg Volume (10D) 405.1K
Key Metrics & Fundamentals
Market Cap
$689.70M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.88 - 17.25
% vs 50 MA
-23.82%
% vs 200 MA
-4.91%
RSI-14
36.5
MACD Histogram
-0.2200
Beta (1Y vs SPY)
2.00
Gross Rev
–
Gross Profit
–
EBITDA
–
COGS
–
Operating Exp
–
Operating Income
–
EBIT
–
Pretax Income
–
Net Income
–
Price & Volume History
Loading chart…
Recent News
Adlai Nortye Announces Oral Presentation for AN4035 Program Update at the Upcoming 38th EORTC-NCI-AACR Symposium
GlobeNewswire · Oct 27, 2026 4:05 PM ET
Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab
GlobeNewswire · Oct 15, 2026 7:00 AM ET
Is Adlai Nortye Ltd. Sponsored ADR (ANL) Stock Outpacing Its Medical Peers This Year?
Zacks · Oct 14, 2026 8:40 AM ET
Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations
GlobeNewswire · Sep 30, 2026 7:00 AM ET
4.8x P B? Adlai Nortye Group (ANL) On Its AN4035 Trial Progress
Simply Wall St. · Sep 15, 2026 1:12 PM ET
Adlai Nortye Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-RAS(ON) Inhibitor-Based ADC
GlobeNewswire · Sep 8, 2026 7:00 AM ET
These 2 ‘Monster Growth’ Stocks Aren’t Done Climbing, Say Analysts
TipRanks · Sep 6, 2026 2:00 PM ET
Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress
GlobeNewswire · Aug 14, 2026 7:00 AM ET
Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia
GlobeNewswire · Aug 3, 2026 7:00 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.